Duan et al 2026 — Resveratrol blocks cGAS-STING via STING ER-Golgi translocation inhibition
One-paragraph summary
Mouse-model + in-vitro mechanistic study testing whether resveratrol — a widely available, OTC, well-characterized polyphenol — blocks the cGAS-STING signalling pathway and attenuates microglial senescence-associated neuroinflammation. D-galactose-induced accelerated-aging mice show cognitive impairment, microglial activation, elevated pro-inflammatory cytokines, and accumulation of cellular-senescence markers. Daily oral resveratrol for three weeks reverses the cognitive impairment, microglial activation, and SASP cytokine elevation (Cxcl-10, IL-1β, others). Mechanistically, unbiased transcriptomic analysis of cultured microglia identifies cGAS-STING as the dominant resveratrol-modulated pathway. Resveratrol inhibits STING translocation from the endoplasmic reticulum to the Golgi apparatus and suppresses TBK1 phosphorylation — blocking the canonical cGAS-STING activation step downstream of cytosolic DNA sensing. For the project's HERV-mitochondrial-inflammation loop, this paper supplies a candidate cheap, OTC-available STING-pathway interrupter that operates at exactly the loop's IFN-amplification step (the STING translocation step). The white paper §7.4 enumerates STING inhibition as the second of three loop-interruption cure-path arms, currently anchored only by clinical-stage candidates for SAVI / Aicardi-Goutières / lupus. Resveratrol becomes a candidate adjunct or pilot-tier intervention that could be tested ahead of clinical-stage STING inhibitors, particularly attractive in HERV-W-positive FM patients pending Q39 confirmation.
Claims as triples
cGAS_STING_pathway — responds_to → resveratrol[evidence: in-vivo mouse + in-vitro microglia transcriptomic; confidence: emerging]microglia — modulates → cognitive_dysfunction[evidence: senescence-associated microglial activation drives cognitive impairment in D-gal model; resveratrol rescue; confidence: emerging]resveratrol — modulates → neuroinflammation_glial[evidence: SASP cytokine reduction (Cxcl-10, IL-1β) post resveratrol; confidence: emerging]cGAS_STING_pathway — causes → neuroinflammation_glial[evidence: STING-translocation inhibition by resveratrol attenuates microglial activation; confidence: established (reinforces existing edge)]
Methods note
In vivo: D-galactose-induced accelerated-aging mouse model (chronic intraperitoneal D-gal). Resveratrol oral gavage daily for three weeks following D-gal injections. Behavioral assays for cognitive performance. Immunohistochemistry, qPCR, Western blot for senescence markers, microglial activation markers, pro-inflammatory cytokines. In vitro: cultured microglia (likely BV2 or primary) with cGAS-STING-activating stimuli; resveratrol intervention; unbiased RNA-seq for transcriptomic mechanism identification. Mechanism-resolution: STING ER → Golgi translocation assay; TBK1 phosphorylation Western blot.
Limitations
- Mouse model — translation to FM is by analogy, not direct demonstration. The D-gal-induced accelerated-aging paradigm is a senescence model, not an FM model. Translation requires demonstration that the same cGAS-STING activation operates in HERV-W-positive FM patients (Q39).
- Resveratrol bioavailability is poor in humans. Oral resveratrol absorption is highly variable; plasma concentrations rarely match mouse-experimental concentrations. Translation may require resveratrol analogs with better PK profiles, or higher-dose regimens.
- No FM cohort data. Whether resveratrol reduces FM symptoms preferentially in HERV-W-positive patients is open.
- Bridging-tier confidence for the FM application. The cGAS-STING / microglial-senescence framework is well-established in the cancer / aging literature; FM-specific operation is the open empirical question.
Open questions raised
- Does resveratrol reduce plasma cell-free mtDNA or ISG signature in HERV-W-positive FM patients? Cheap pragmatic pilot; existing safety profile bypasses IND.
- Does resveratrol synergize with idebenone (mitochondrial protection) or temelimab (HERV-W ENV neutralization) in stratified HERV-W-positive FM? Triple-mechanism intervention design becomes possible.
- Are there other STING-pathway-interrupting nutraceuticals or repurposed drugs that operate at the same translocation step? Resveratrol is a starting point; the broader class deserves a screen.
Triangulation notes
- Adds a candidate cheap, OTC-available STING-pathway interrupter to the HERV-mito-loop cure-path arms. White paper §7.4 currently lists three intervention points: temelimab (anti-HERV-W ENV mAb), STING inhibitors (clinical-stage compounds), and mitochondrial-protective agents (idebenone / MitoQ / elamipretide). Resveratrol joins the second category as the most accessible candidate.
- Bridges to He et al 2026 (P2X7-cGAS-STING in chronic-stress depression). Both papers establish cGAS-STING-pathway interruption as a chain-agnostic intervention — operating downstream of multiple upstream drivers (HERV-W ENV, microglial P2X7, D-gal-induced senescence). Resveratrol's chain-agnostic interruption is exactly the property the project values for FM, given upstream heterogeneity.
- Compatible with white paper §10.7 STING-inhibition monitoring. That section recommends quarterly tracking of STING-inhibitor approvals; resveratrol provides a parallel pragmatic-pilot path that doesn't require waiting for a clinical-stage approval.
Bridges
- New candidate B16 — cGAS-STING-pathway-interrupting nutraceuticals (resveratrol as anchor; broader class candidate). Drug-class-defined bridge linking aging research, microglial-senescence research, and the project's HERV-mito-loop framework.
- Strengthens the existing HERV-mito-loop framework by adding a third intervention point at the STING-translocation step, complementing the upstream HERV-W ENV-block (temelimab) and downstream mitochondrial-protection (idebenone) arms.